Developer docs
API playgroundTry for free, no card

Search company profiles

Moleac

Full company profile

uuid000dj7v

Namestring
Moleac
Legal namestring
Moleac Pte Ltd
Websiteurl
moleac.com
Company typeenum
Private
Founded yearint
2003
Descriptiontext

Moleac is a privately held Singapore-based biopharmaceutical company founded in 2003 that develops and commercializes a single core product, NeuroAiD (marketed in its updated form as NeuroAiD II), an oral treatment derived from a proprietary complex herbal formulation. The product is positioned as the world's first post-stroke recovery treatment, designed to help patients with established neurological deficits from stroke, traumatic brain injury, or spinal cord injury recover functional independence by amplifying endogenous brain repair processes; it is also positioned to support cognitive function in Alzheimer's Disease. Its clinical and manufacturing credentials rest on more than 90 peer-reviewed publications and a Gold accreditation from the independent nonprofit Empowered By Evidence (EBE) awarded in February 2026.

The company generates revenue through two channels: direct-to-consumer e-commerce sales via moleac.com (payment via PayPal, credit card, or wire transfer, with international shipping from Singapore) and exclusive country-level distribution partnerships with local pharmaceutical companies that handle in-market sales and HCP engagement. NeuroAiD is available in over 30 countries, with recent expansion activity in Mongolia (via Monos Group, May 2026) and active commercial efforts across Indonesia, Vietnam, Taiwan, and broader Southeast Asia.

Moleac's go-to-market emphasizes healthcare professional engagement through sponsored symposia at major neurology conferences (e.g., ESOC 2026 in Maastricht), hosted summits (Neurological Disorders Summit in Da Nang, Neurovascular Summit in Taipei), and ongoing collaboration with stroke-focused physician networks such as the Asian Stroke Advisory Panel (ASAP). The firm employs 11-50 people, is founder/management-owned with no disclosed institutional investors, and operates as Moleac Pte Ltd from its headquarters at Helios, Biopolis Way, Singapore.

Short descriptiontext

Moleac is a Singapore-based biopharmaceutical company founded in 2003 that develops and markets NeuroAiD II, an oral herbal treatment for post-stroke recovery and brain injury rehabilitation, sold direct-to-consumer and via exclusive distributors in 30+ countries.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersSingapore, Singapore
HQ citystring
Singapore
HQ countrystring
Singapore
HQ regionstring
Asia
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
neurorehabilitation pharmaceuticals, post-stroke recovery treatments, natural product neurology, brain injury therapeutics, Alzheimer's cognitive support
Industry1 code
PRIMARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code2 codes
  • Pharmaceutical and Medicine Manufacturing32541
  • Medicinal and Botanical Manufacturing325411
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Medicinal Chemicals & Botanical Products2833
Product category
Neurorehabilitation Pharmaceuticals
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Product Sales (NeuroAiD/NeuroAiDII)
TypeOne Time License
Description

Direct-to-consumer sales through the company's e-commerce website (moleac.com) with products shipped internationally from Singapore. Sales are processed through PayPal or credit card for online orders, with wire transfer available for phone/email enquiries.

moleac.com
2International Distribution Partnerships
TypeSubscription Recurring
Description

Products distributed through exclusive partnership agreements with local pharmaceutical companies in various countries (e.g., Monos Group in Mongolia, PT Ferron Par Pharmaceuticals in Indonesia), expanding market reach globally.

moleac.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Marketing or Sales, Supply Chain, Operations
GTM typeB2C
B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1NeuroAiD
Description

The world's first post-stroke recovery treatment, an oral treatment helping patients of brain and spinal cord injuries who suffer from established deficits to recover their functional independence in addition to rehabilitation therapy and exercises. Also supports cognitive functions in Alzheimer's Disease.

moleac.com
+1 more record
Core offering1 text field

Moleac develops and commercializes NeuroAiD/NeuroAiD II, an oral natural pharmacological treatment designed to help patients with established neurological deficits from stroke, traumatic brain injury, or spinal cord injury recover functional independence. The product is also indicated to support cognitive function in Alzheimer's Disease, and is sold directly via the company's e-commerce website and through exclusive pharmaceutical distribution partners across 30+ countries.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Over 90 scientific publications supporting the product's efficacy and safety
+2 more records
Product overview1 text field

Moleac is a biopharmaceutical company focused on neurology, offering a single core product: NeuroAiD II (also marketed as NeuroAiD). This is an oral pharmacological treatment designed to help patients recover functional independence after stroke or traumatic brain injury by amplifying endogenous processes of brain repair. The company also provides educational content about neurological conditions including stroke, TBI, and Alzheimer's disease, along with a stroke recovery coach tool. Product is developed with scientific excellence and evidence-based approach, with over 90 publications supporting the formulation.

Product and service1 record
1NeuroAiD II
CategoryNeurorehabilitation Pharmaceuticals
Description

NeuroAiD II is an oral treatment for patients of brain and spinal cord injuries who suffer from established deficits, designed to help them recover functional independence in addition to rehabilitation therapy and exercises. It also supports cognitive functions in Alzheimer's Disease. The product amplifies endogenous processes of brain repair and is available in over 30 countries worldwide.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-05-04
Description

Monos Group is Mongolia's leading healthcare and pharmaceutical company, founded in 1990 and recognized for its innovation, research, and nationwide impact. Partnered with Moleac for the successful launch of NeuroAiD™II in Mongolia, committed to advancing clinical knowledge in neurorehabilitation and improving neurological recovery outcomes for patients in Mongolia.

2PT Ferron Par Pharmaceuticals
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-28
Description

PT Ferron Par Pharmaceuticals collaborated with Moleac to host a Neurovascular Summit in Taipei, focusing on brain injury management. The meeting brought together healthcare professionals from across Indonesia for valuable exchange and collaboration to improve patient outcomes.

moleac.com
3Asian Stroke Advisory Panel (ASAP)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Moleac is proud to support ASAP's mission to advance acute stroke management and remains committed to fostering impactful conversations and the sharing of knowledge. ASAP is a panel uniting leaders in neurology across Asia to push the boundaries of stroke care.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Developer of nerinetide and other neuroprotection therapies for acute ischemic stroke, comparable to Moleac as a specialty neurology company addressing stroke treatment gaps.

2Athersys
TypeDirect peer
Description

Developed MultiStem cell therapy for ischemic stroke and other neurological indications, directly comparable as a small-cap company targeting the post-stroke recovery space.

3Boehringer Ingelheim
TypeBroad incumbent
Description

Global pharmaceutical company with Actilyse (alteplase) for acute ischemic stroke, representing an established incumbent in stroke therapeutics and a benchmark for clinical credibility in the space.

TypeBroad incumbent
Description

Major Japanese pharmaceutical company with neurology portfolio and strong Asia-Pacific presence, comparable to Moleac in its regional commercialization footprint and neurological focus.

TypeBroad incumbent
Description

Large multinational biopharmaceutical company with a broad neurology franchise spanning multiple sclerosis, Alzheimer's, and stroke-related conditions, serving as a major incumbent competitor in CNS therapeutics.

TypeDirect peer
Description

Clinical-stage biopharmaceutical company developing treatments for stroke and other neurological conditions, directly comparable to Moleac's focus on post-stroke recovery therapeutics.

TypeRegional player
Description

Leading Chinese traditional Chinese medicine (TCM) pharmaceutical company, comparable to Moleac as a botanical/herbal-based pharmaceutical with neurology-related indications, primarily operating in the China market.

TypeDirect peer
Description

Cell therapy developer focused on stroke disability and other neurological conditions, comparable to Moleac in targeting post-stroke functional recovery.

TypeRegional player
Description

Korean specialty pharmaceutical company with neurology and rehabilitation product portfolio, comparable to Moleac in pursuing neurology therapeutics in Asian markets.

TypeDirect peer
Description

Clinical-stage biotech developing GM604 and related multi-target peptides for ALS, stroke, and other neurological conditions, comparable to Moleac in pursuing novel therapeutics for CNS indications.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Moleac

Neurorehabilitation Pharmaceuticalsmoleac.com

Moleac is a Singapore-based biopharmaceutical company founded in 2003 that develops and markets NeuroAiD II, an oral herbal treatment for post-stroke recovery and brain injury rehabilitation, sold direct-to-consumer and via exclusive distributors in 30+ countries.

What Moleac does

Moleac is a privately held Singapore-based biopharmaceutical company founded in 2003 that develops and commercializes a single core product, NeuroAiD (marketed in its updated form as NeuroAiD II), an oral treatment derived from a proprietary complex herbal formulation. The product is positioned as the world's first post-stroke recovery treatment, designed to help patients with established neurological deficits from stroke, traumatic brain injury, or spinal cord injury recover functional independence by amplifying endogenous brain repair processes; it is also positioned to support cognitive function in Alzheimer's Disease. Its clinical and manufacturing credentials rest on more than 90 peer-reviewed publications and a Gold accreditation from the independent nonprofit Empowered By Evidence (EBE) awarded in February 2026.

The company generates revenue through two channels: direct-to-consumer e-commerce sales via moleac.com (payment via PayPal, credit card, or wire transfer, with international shipping from Singapore) and exclusive country-level distribution partnerships with local pharmaceutical companies that handle in-market sales and HCP engagement. NeuroAiD is available in over 30 countries, with recent expansion activity in Mongolia (via Monos Group, May 2026) and active commercial efforts across Indonesia, Vietnam, Taiwan, and broader Southeast Asia.

Moleac's go-to-market emphasizes healthcare professional engagement through sponsored symposia at major neurology conferences (e.g., ESOC 2026 in Maastricht), hosted summits (Neurological Disorders Summit in Da Nang, Neurovascular Summit in Taipei), and ongoing collaboration with stroke-focused physician networks such as the Asian Stroke Advisory Panel (ASAP). The firm employs 11-50 people, is founder/management-owned with no disclosed institutional investors, and operates as Moleac Pte Ltd from its headquarters at Helios, Biopolis Way, Singapore.

Moleac firmographics

Firmographics
Name
Moleac
Legal name
Moleac Pte Ltd
Website
https://moleac.com
Company type
Private
Founded year
2003
Operating status
Operating
Headcount range
51–100 employees
Short description
Moleac is a Singapore-based biopharmaceutical company founded in 2003 that develops and markets NeuroAiD II, an oral herbal treatment for post-stroke recovery and brain injury rehabilitation, sold direct-to-consumer and via exclusive distributors in 30+ countries.
Ownership category
akta.pro rank

Moleac industry classification

Industry
Product category
Neurorehabilitation Pharmaceuticals
NAICS
Pharmaceutical and Medicine Manufacturing (32541), Medicinal and Botanical Manufacturing (325411)
SIC
Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)
akta.pro industry
PRIMARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Neurorehabilitation pharmaceuticals
  • Post-stroke recovery treatments
  • Natural product neurology
  • Brain injury therapeutics
  • Alzheimer's cognitive support

Where Moleac is headquartered

Location

Headquarters

HQ city
Singapore
HQ country
Singapore
HQ region
Asia

Offices1 record

Markets served

Moleac business model

Business model
GTM type
B2C
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Marketing or Sales, Supply Chain, Operations

Revenue model

  1. Product Sales (NeuroAiD/NeuroAiDII): Direct-to-consumer sales through the company's e-commerce website (moleac.com) with products shipped internationally from Singapore. Sales are processed through PayPal or credit card for online orders, with wire transfer available for phone/email enquiries.
  2. International Distribution Partnerships: Products distributed through exclusive partnership agreements with local pharmaceutical companies in various countries (e.g., Monos Group in Mongolia, PT Ferron Par Pharmaceuticals in Indonesia), expanding market reach globally.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels6 records

Moleac product offering

Product offering

Core offering

Moleac develops and commercializes NeuroAiD/NeuroAiD II, an oral natural pharmacological treatment designed to help patients with established neurological deficits from stroke, traumatic brain injury, or spinal cord injury recover functional independence. The product is also indicated to support cognitive function in Alzheimer's Disease, and is sold directly via the company's e-commerce website and through exclusive pharmaceutical distribution partners across 30+ countries.

Product overview

Moleac is a biopharmaceutical company focused on neurology, offering a single core product: NeuroAiD II (also marketed as NeuroAiD). This is an oral pharmacological treatment designed to help patients recover functional independence after stroke or traumatic brain injury by amplifying endogenous processes of brain repair. The company also provides educational content about neurological conditions including stroke, TBI, and Alzheimer's disease, along with a stroke recovery coach tool. Product is developed with scientific excellence and evidence-based approach, with over 90 publications supporting the formulation.

Differentiator

Problem solved

Functional benefit

Brands

  • NeuroAiD: The world's first post-stroke recovery treatment, an oral treatment helping patients of brain and spinal cord injuries who suffer from established deficits to recover their functional independence in addition to rehabilitation therapy and exercises. Also supports cognitive functions in Alzheimer's Disease.
  • NeuroAiD II

Products and services

  • NeuroAiD II NeuroAiD II is an oral treatment for patients of brain and spinal cord injuries who suffer from established deficits, designed to help them recover functional independence in addition to rehabilitation therapy and exercises. It also supports cognitive functions in Alzheimer's Disease. The product amplifies endogenous processes of brain repair and is available in over 30 countries worldwide.

Quantifiable outcome

  • Over 90 scientific publications supporting the product's efficacy and safety
  • +2 more outcomes

Companies that use Moleac

Customer profile

Segments3 records

Ideal customer profiles3 records

Moleac technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Moleac partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • Monos GroupcoreChannel Partner/ Reseller/ Distributor · 4 May 2026Monos Group is Mongolia's leading healthcare and pharmaceutical company, founded in 1990 and recognized for its innovation, research, and nationwide impact. Partnered with Moleac for the successful launch of NeuroAiD™II in Mongolia, committed to advancing clinical knowledge in neurorehabilitation and improving neurological recovery outcomes for patients in Mongolia.
  • PT Ferron Par PharmaceuticalscoreStrategic or Co-development Partner · 28 April 2026PT Ferron Par Pharmaceuticals collaborated with Moleac to host a Neurovascular Summit in Taipei, focusing on brain injury management. The meeting brought together healthcare professionals from across Indonesia for valuable exchange and collaboration to improve patient outcomes.
  • Asian Stroke Advisory Panel (ASAP)coreStrategic or Co-development PartnerMoleac is proud to support ASAP's mission to advance acute stroke management and remains committed to fostering impactful conversations and the sharing of knowledge. ASAP is a panel uniting leaders in neurology across Asia to push the boundaries of stroke care.

Scale indicators3 records

Recent moves6 records

Expansion highlights4 records

Moleac competitors and assessment

Company assessment

Direct peers

  • NoNO Inc. Developer of nerinetide and other neuroprotection therapies for acute ischemic stroke, comparable to Moleac as a specialty neurology company addressing stroke treatment gaps.
  • Athersys: Developed MultiStem cell therapy for ischemic stroke and other neurological indications, directly comparable as a small-cap company targeting the post-stroke recovery space.
  • DiaMedica Therapeutics: Clinical-stage biopharmaceutical company developing treatments for stroke and other neurological conditions, directly comparable to Moleac's focus on post-stroke recovery therapeutics.
  • ReNeuron: Cell therapy developer focused on stroke disability and other neurological conditions, comparable to Moleac in targeting post-stroke functional recovery.
  • Genervon Biopharmaceuticals: Clinical-stage biotech developing GM604 and related multi-target peptides for ALS, stroke, and other neurological conditions, comparable to Moleac in pursuing novel therapeutics for CNS indications.

Broad incumbents

  • Boehringer Ingelheim: Global pharmaceutical company with Actilyse (alteplase) for acute ischemic stroke, representing an established incumbent in stroke therapeutics and a benchmark for clinical credibility in the space.
  • Daiichi Sankyo: Major Japanese pharmaceutical company with neurology portfolio and strong Asia-Pacific presence, comparable to Moleac in its regional commercialization footprint and neurological focus.
  • Biogen: Large multinational biopharmaceutical company with a broad neurology franchise spanning multiple sclerosis, Alzheimer's, and stroke-related conditions, serving as a major incumbent competitor in CNS therapeutics.

Regional players

  • Yiling Pharmaceutical: Leading Chinese traditional Chinese medicine (TCM) pharmaceutical company, comparable to Moleac as a botanical/herbal-based pharmaceutical with neurology-related indications, primarily operating in the China market.
  • Pharmascience (Korea): Korean specialty pharmaceutical company with neurology and rehabilitation product portfolio, comparable to Moleac in pursuing neurology therapeutics in Asian markets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Moleac social profiles

Digital presence

Moleac compliance and trust

Trust signal

Compliance1 record

Moleac financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Moleac leadership team

Management profile

Number of profiles

Profiles3 records

Moleac funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Moleac M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Moleac

What does Moleac do?

Moleac develops and commercializes NeuroAiD/NeuroAiD II, an oral natural pharmacological treatment designed to help patients with established neurological deficits from stroke, traumatic brain injury, or spinal cord injury recover functional independence. The product is also indicated to support cognitive function in Alzheimer's Disease, and is sold directly via the company's e-commerce website and through exclusive pharmaceutical distribution partners across 30+ countries.

Is Moleac a public or private company?

Moleac is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Moleac founded?

Moleac was founded in 2003. It employs 51 to 100 people.

Where is Moleac based?

Moleac is headquartered in Singapore, Singapore, in the Asia region.

How does Moleac make money?

Two revenue lines are on record. Product Sales (NeuroAiD/NeuroAiDII) is the primary driver. The others are international Distribution Partnerships.

Who are Moleac's main competitors?

Direct peers on record are NoNO Inc., Athersys, DiaMedica Therapeutics, ReNeuron and Genervon Biopharmaceuticals. Broad incumbents are Boehringer Ingelheim, Daiichi Sankyo and Biogen. Regional players are Yiling Pharmaceutical and Pharmascience (Korea).

Does Moleac have an API?

No public API is recorded for Moleac.

What industry is Moleac in?

Moleac's product category is Neurorehabilitation Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAF, Neurology & Psychiatry (CNS) Pharmaceuticals. Its NAICS code is 32541 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
News-MedicalInternational task force outlines roadmap for precision stroke recoveryAn international task force co-led by Georgetown University experts has published a roadmap in the International Journal of Stroke to standardize the use of genetic and blood biomarkers for precision stroke recovery. The framework calls for harmonized data collection and larger, multi-center studies to understand the biological processes of brain repair and develop new biotherapeutics. Moleac provided unrestricted grant support for the initiative's meeting.PR NewswireMoleac is pleased to announce that NeuroAiD™II has been awarded Gold accreditation by Empowered By Evidence.Moleac announced that its product NeuroAiD™II has received Gold accreditation from Empowered By Evidence (EBE), an independent international non-profit organization based in New York. The accreditation recognizes the product's robust clinical evidence, unique formulation, and rigorous manufacturing quality control. The CEO stated the recognition validates the company's pioneering approach to developing complex herbal formulations supported by over 90 publications.TrendsresearchNeuro-Synchronized AI Learning Systems: The Future of Personalized EducationThe article analyzes the integration of Brain-Computer Interfaces (BCIs) with Artificial Intelligence to create Neuro-Synchronized Learning Systems, such as AttentivU, for personalized education. It highlights the potential of these systems to tailor content based on real-time cognitive load and engagement while emphasizing the necessity of strict data privacy protocols, exemplified by practices at Moleac in Singapore. The discussion also covers ethical standards and regulatory trends required to manage sensitive neural data in educational settings.TrendsresearchNeuro-Synchronized AI Learning Systems: The Future of Personalized EducationThe article analyzes the integration of Brain-Computer Interfaces (BCIs) with Artificial Intelligence to create Neuro-Synchronized AI Learning Systems, such as AttentivU, for personalized education. It highlights specific systems like 'Let’s Learn' and 'Focus' that adapt content based on real-time neural signals to support special needs and neurodivergent learners. The report also outlines strict ethical and privacy protocols, including data anonymization at Moleac in Singapore, required for handling sensitive neurophysiological data.TrendsresearchNeuro-Synchronized AI Learning Systems: The Future of Personalized EducationThe article evaluates Neuro-Synchronized AI Learning Systems, such as AttentivU, which integrate Brain-Computer Interfaces with Artificial Intelligence to personalize education by monitoring neural signals and adapting content in real-time. It highlights the potential of these tools for special needs education while emphasizing the critical need for strict data privacy protocols, citing Moleac in Singapore as an example of secure data handling. The piece concludes that global regulatory frameworks must evolve to address ethical concerns surrounding the collection and use of sensitive neurophysiological data in educational settings.TrendsresearchNeuro-Synchronized AI Learning Systems: The Future of Personalized EducationThe article analyzes the integration of Brain-Computer Interfaces (BCIs) with Artificial Intelligence to create Neuro-Synchronized AI Learning Systems, such as AttentivU, for personalized education. It highlights specific applications like 'Let’s Learn' and 'Focus' for neurodivergent learners and details data privacy protocols managed by Moleac in Singapore. The text further examines the ethical standards, regulatory trends, and policy frameworks required to govern these technologies in educational settings.GlobeNewswireMoleac’s NeuroAiD™II Improves Post-Concussion Symptoms, Quality of Life, and Mood after a Mild Traumatic Brain InjuryMoleac announced results from the SAMURAI double-blind study in mild traumatic brain injury patients receiving NeuroAiD II for six months. The NeuroAiD II group showed significant improvements in post-concussion symptoms, quality of life, and mood compared to placebo, with benefits persisting after treatment discontinuation.GlobeNewswireSLT (CognivAiD™) Improves Memory and Cognition in Individuals With Mild Cognitive Impairment: Clinical Trial ResultsMoleac reported results from an investigator-led trial of SLT (CognivAiD) in mild cognitive impairment, showing significant improvements in episodic memory and executive function over 12 weeks. The treatment was well-tolerated, and the findings expand its indication beyond vascular dementia. The company noted that about 17% of people aged 60 and above are affected by MCI.GlobeNewswireMoleac launches CognivAiD™, a novel targeted product for vascular dementiaMoleac launched CognivAiD, a formulation of Ginkgo, Ginseng, and Saffron extracts, for vascular dementia on October 29, 2022. The product showed disease-modifying benefits on VaDAS-Cog and ADCS-CGIC scales with a favorable safety profile. It targets vascular protection, vasoregulation, and neuroinflammation, addressing a gap in treatment.PR NewswireNeuroAiD(TM)II holds promise as a safe add-on therapy to standard Alzheimer Disease symptomatic treatments and may have a disease modifying effect by delaying disease progressionMoleac announced the release of the ATHENE study results, published in the Journal of the American Medical Directors Association, evaluating NeuroAiD™II as an add-on therapy for mild to moderate Alzheimer's Disease patients. The 6-month randomized double-blind placebo-controlled trial with 125 subjects from Singapore demonstrated long-term safety with no increase in adverse events and showed statistically significant cognitive improvement at 9 months for the early treatment group compared to placebo. The study results suggest NeuroAiD™II may have disease-modifying potential by slowing Alzheimer's progression, though the researchers note these findings require confirmation in larger and longer studies.